Roche: Bank of America upgrades stock

(CercleFinance.com) - Bank of America announced on Friday that it had upgraded its recommendation on Roche shares from 'neutral' to 'buy', with a target price raised from 290 CHF to 340 CHF.


In addition to the Swiss pharmaceutical company's obesity franchise, the analyst said he was particularly interested in the potential of three drug projects, which he believes could generate sales of over $5bn.

These are Giredestrant (breast cancer), Fenebrutinib (multiple sclerosis) and Prasinezumab (Parkinson's disease), the broker adds.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.